Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia
- PMID: 33958577
- PMCID: PMC8102516
- DOI: 10.1038/s41398-021-01385-9
Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia
Abstract
Schizophrenia disorder remains an unsolved puzzle. However, the integration of recent findings from genetics, molecular biology, neuroimaging, animal models and translational clinical research offers evidence that the synaptic overpruning hypothesis of schizophrenia needs to be reassessed. During a critical period of neurodevelopment and owing to an imbalance of excitatory glutamatergic pyramidal neurons and inhibitory GABAergic interneurons, a regionally-located glutamate storm might occur, triggering excessive dendritic pruning with the activation of local dendritic apoptosis machinery. The apoptotic loss of dendritic spines would be aggravated by microglia activation through a recently described signaling system from complement abnormalities and proteins of the MHC, thus implicating the immune system in schizophrenia. Overpruning of dendritic spines coupled with aberrant synaptic plasticity, an essential function for learning and memory, would lead to brain misconnections and synaptic inefficiency underlying the primary negative symptoms and cognitive deficits of schizophrenia. This driving hypothesis has relevant therapeutic implications, including the importance of pharmacological interventions during the prodromal phase or the transition to psychosis, targeting apoptosis, microglia cells or the glutamate storm. Future research on apoptosis and brain integrity should combine brain imaging, CSF biomarkers, animal models and cell biology.
Conflict of interest statement
This work was partially supported by the Catalan Pons Balmes Grant (FCRB_PB_2018) and by the Spanish Ministry of Economy, Industry and Competitiveness, Carlos III Health Institute, Fondo de Investigación Sanitaria (FIS)—The European Regional Development Fund (FEDER – una manera de hacer Europa) (PI18/01005) and the Government of Catalonia, Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement (2017SGR1355; 2017SGR1562). E.P. has received honoraria and/or research grants from the Fondo de Investigación Sanitaria of the Spanish Ministry of Science and Innovation, MINECO, the Catalan Pons Balmes Grant, Fundació la Marató de TV3 of Catalonia, Janssen-Cilag, GlaxoSmithKline, Ferrer, and ADAMED. P.G. has received research grants from the Fondo de Investigación Sanitaria of the Spanish Ministry of Science and Innovation, the Catalan Pons Balmes Grant, and Janssen-Cilag. None of the authors received any payment from the pharmaceutical industry to write this article.
Figures
References
-
- McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia—an overview. JAMA Psychiatry. 2019;30:1–10. - PubMed
-
- Weinberger D. R. The pathogenesis of schizophrenia: a neurodevelopmental theory. In: The Neurology of Schizophrenia (eds R. A. Nasrallah & D. R. Weinberger). (Elsevier, 1986; 387–405).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
